Tag: managers

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

CHICAGO, June 10, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, along with Morningstar, a leading provider of independent investment insights, today...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation of shares to a director of the board of Alvotech in accordance with his remuneration package.

Live, Boot Camp-Style Training Now Available to Federal, State and Local Government AgenciesPLANO, Texas and RESTON, Va., June 10, 2026 /PRNewswire/ -- Simplilearn, a...

Live, Boot Camp-Style Training Now Available to Federal, State and Local Government AgenciesPLANO, Texas and RESTON, Va., June 10, 2026 /PRNewswire/ -- Simplilearn, a...

Recognition for 10-year performance underscores Lear's differentiated, research-driven approach to active managementDALLAS, June 10, 2026 /PRNewswire/ -- Lear Investment Management ("Lear"), a Dallas-based SEC-registered...

PORTLAND, Ore., June 10, 2026 /PRNewswire/ -- The Dyrt, the app to get the best campsites, built by the largest RVing and camping community...

        

Charles Héaulmé has reported to have made transactions with Suominen Corporation's shares. The transactions are presented below as a summary, and in detail as per the disclosure requirement.

Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations

Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.